Business Context and Reporting Period
This Form 8-K Current Report was filed by Pacific Biosciences of California, Inc. on September 12, 2012. The report discloses a corporate governance event: the appointment of a new member to the Board of Directors.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial figure disclosed relates to director compensation: an annual retainer of $35,000 and a stock option grant for 35,000 shares.
Material Changes
The material change reported is the addition of Lucy Shapiro, Ph.D., as a Class I director effective September 12, 2012. Dr. Shapiro is a distinguished academic and former director of Anacor Pharmaceuticals and Gen-Probe.
Guidance, Outlook, and Risks
The filing contains no management guidance, outlook, risk factors, or discussion of contingencies. It strictly reports the board appointment and references a press release furnished as an exhibit.
Investor Verification Checklist
- Verify the effective date of Dr. Shapiro's board appointment (September 12, 2012).
- Confirm the compensation package: $35,000 annual retainer and 35,000 share stock option grant.
- Review Dr. Shapiro's background as a Stanford University professor and former director of Anacor Pharmaceuticals and Gen-Probe.
- Note that this filing does not provide updated financial performance metrics.